Institut f

1
Quantitative Assessment of Resistance to Fusion
Inhibitors (T-20) in a Replicative Phenotyping
Assay
POSTER 2.22
Institut für medizinische Mikrobiologie Basel
Vincent BRONDANI, François HAMY and Thomas
KLIMKAIT Institute of Medical Microbiology,
University of Basel, Switzerland InPheno AG,
Basel, Switzerland
BACKGROUND Fusion between HIV-env and target
cells is now accepted as a valid target for
therapeutic intervention. Nevertheless, like
other drugs used in HAART, this new class of
fusion inhibitors can experience a rapid escape
of HIV via rather stochastic mutations of the HIV
genome with subsequent selection upon
drug-pressure. We have developed the replicative
phenotyping system PhenoTect, validated as
diagnostic resistance test platform for protease
and RT inhibitors. We aimed at assessing the
amenability of PhenoTect to analyse resistance
against fusion inhibitors.
Figure 7 shows a direct comparison of IC50 values
determined either in the single cycle (blue bars)
or the PhenoTect format (red bars). Results
demonstrate the superiority of the replicative
format in discriminating susceptibility to T-20
for the examined gp41-mutants.
2
(No Transcript)